The meta‐analysis revealed that in HCC patients treated with PD‐1/PD‐L1 inhibitors, a significantly higher ORR was observed in PD‐L1‐positive patients than in PD‐L1‐negative patients (26% vs. 18%). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.